Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Pemetrexed,PMTX101,2021,USA,MDV,350,68,45,55,26.5,60,85,5,15,30,40,15,50,25,15,10,20,35,45,18,8,5,12,7,25,65,50,Cisplatin + Pemetrexed,Carboplatin + Pemetrexed,Pemetrexed,Cisplatin + Pemetrexed,0,0,0,20,70,55,15,45,40,60,2
Pemetrexed,PMTX102,2022,Canada,Claim Database,420,72,52,48,27.1,55,80,3,12,28,45,15,48,27,16,9,18,33,49,20,10,6,14,8,22,68,52,Carboplatin + Pemetrexed,Cisplatin + Gemcitabine,Pemetrexed,Carboplatin + Pemetrexed,0,0,0,22,72,58,12,48,40,65,2.5
Pemetrexed,PMTX103,2023,UK,MDV,280,65,48,52,25.8,65,90,7,18,32,35,15,52,23,14,11,22,37,41,16,7,4,11,6,28,62,48,Cisplatin + Pemetrexed,Carboplatin + Paclitaxel,Pemetrexed,Vinorelbine + Cisplatin,0,0,0,18,68,52,18,42,40,55,1.8
Pemetrexed,PMTX104,2023,Germany,Claim Database,480,70,50,50,26.9,58,82,4,14,29,42,15,49,26,17,8,19,34,47,19,9,5,13,7,24,66,51,Carboplatin + Pemetrexed,Cisplatin + Docetaxel,Pemetrexed,Carboplatin + Paclitaxel,0,0,0,21,71,57,13,47,40,62,2.3
